Page last updated: 2024-08-23

quinapril and Scleroderma, Limited

quinapril has been researched along with Scleroderma, Limited in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnes, T; Black, CM; Camilleri, J; Chakravarty, K; Denton, CP; Doré, CJ; Emery, P; Gliddon, AE; Griffiths, B; Herrick, A; Hickling, P; Hopkinson, ND; Lanyon, P; Laversuch, C; Lawson, T; Maddison, PJ; Mallya, R; McHugh, N; Moots, R; Nisar, M; Rhys-Dillon, C; Sheeran, T	1

Trials

1 trial(s) available for quinapril and Scleroderma, Limited

Article	Year
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis and rheumatism, 2007, Volume: 56, Issue:11 Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebos; Quinapril; Raynaud Disease; Scleroderma, Limited; Tetrahydroisoquinolines; Treatment Outcome	2007

Article

Year

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.

Arthritis and rheumatism, 2007, Volume: 56, Issue:11

Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebos; Quinapril; Raynaud Disease; Scleroderma, Limited; Tetrahydroisoquinolines; Treatment Outcome

2007